Selvita Establishes Its UK Subsidiary in Cambridge

07-May-2015 - Selvita is opening its first office in the United Kingdom. The office is based in Cambridge, considered to be one of the most significant biotechnology clusters in the world. The new office will be responsible for supporting the ongoing projects for the customers from the UK and Northern Ireland, ...

Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence

11-Nov-2014 - Felicitex Therapeutics and Selvita announced that they have entered into a strategic collaboration to develop breakthrough personalized cancer therapeutics for some of the deadliest and most resistant cancers, such as pancreatic, colon, ovarian, lung and hematopoietic tumors.During the first ...

H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration

Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology

27-May-2014 - H3 Biomedicine Inc. and Selvita announced that they have achieved the first research milestone in their strategic collaboration to develop breakthrough precision medicines for cancers. The companies have validated the importance and druggability of a kinase target in a specific genetic context ...

Selvita and Orion Pharma Achieve a Research Milestone in Alzheimer’s Disease Program

03-Jul-2012 - Selvita S.A. announced that its collaboration with Orion Corporationon SEL103 program, for the symptomatic treatment of Alzheimer’s disease has reached the main research milestone and that the jointly discovered molecules from two different chemical families will progress into further ...

Selvita Ranked the No. 1 Rising Star in Deloitte Technology Fast 50 Central Europe

20-Oct-2011 - Selvita S.A. has been ranked as the no.1 Rising Star within this year’s contest of Deloitte Technology Fast 50 in Central Europe.The Central Europe Technology Fast 50 program, is part of a global effort by Deloitte to identify the fastest growing technology companies all over the world, which ...

Selvita Signs a Computational Chemistry Services Agreement with The Institutes for Pharmaceutical Discovery, USA

06-Apr-2011 - Selvita announced an agreement with the Institutes for Pharmaceutical Discovery (IPD) in Branford, CT, USA to provide computational chemistry services to IPD.The aim of this agreement is to identify novel chemical compounds that inhibit the activity of a novel protein target, proposed by IPD. ...

Selvita Appoints Piotr Prelich as a Vice President of Sales and Marketing

26-Nov-2010 - Selvita announced the appointment of Mr. Piotr Prelich to the position of Vice President of Sales and Marketing. Mr. Prelich will be responsible for the further establishment of Selvita’s brand in the pharmaceutical preclinical outsourcing market, both in Poland and abroad, as well as for the ...

Selvita Signs a Drug Discovery Services Contract With Rottapharm Madaus

22-Jul-2010 - Rottapharm Madaus and Selvita announced signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic ...

Selvita And Orion Pharma Will Collaborate on SEL103 - Alzheimer’s Disease Program

09-Jul-2010 - Selvita sp. z o.o. and Orion Corporation from Espoo, Finland announced that they have entered into a global collaboration to jointly develop and commercialize SEL103, Selvita’s proprietary program for the treatment of Alzheimer’s disease and other cognitive disorders. Selvita will be responsible ...

Selvita appoints Dr. Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board

14-May-2008 - Selvita Sp. z o.o. announced the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita's drug research projects. After the first experience in 2002 as a Strategic Database Manager at Sanofi Pasteur MSD, Dr ...